BR112023020506A2 - Métodos de tratamento de inflamação - Google Patents

Métodos de tratamento de inflamação

Info

Publication number
BR112023020506A2
BR112023020506A2 BR112023020506A BR112023020506A BR112023020506A2 BR 112023020506 A2 BR112023020506 A2 BR 112023020506A2 BR 112023020506 A BR112023020506 A BR 112023020506A BR 112023020506 A BR112023020506 A BR 112023020506A BR 112023020506 A2 BR112023020506 A2 BR 112023020506A2
Authority
BR
Brazil
Prior art keywords
treatment methods
inflammation treatment
inflammation
methods
inflammasomes
Prior art date
Application number
BR112023020506A
Other languages
English (en)
Inventor
Gary Barnette Kester
S Steiner Mitchell
Original Assignee
Veru Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veru Inc filed Critical Veru Inc
Publication of BR112023020506A2 publication Critical patent/BR112023020506A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

métodos de tratamento de inflamação. a presente invenção refere-se a métodos de tratamento de inflamação utilizando compostos que rompem o citoesqueleto, causando a despolimerização dos microtúbulos e prevenindo ou reduzindo a montagem de inflamassomas ativados.
BR112023020506A 2021-04-05 2021-08-04 Métodos de tratamento de inflamação BR112023020506A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163171013P 2021-04-05 2021-04-05
PCT/US2021/044572 WO2022216308A1 (en) 2021-04-05 2021-08-04 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
BR112023020506A2 true BR112023020506A2 (pt) 2023-11-21

Family

ID=83545905

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020506A BR112023020506A2 (pt) 2021-04-05 2021-08-04 Métodos de tratamento de inflamação

Country Status (11)

Country Link
US (1) US20240180879A1 (pt)
EP (1) EP4320151A1 (pt)
JP (1) JP2024512816A (pt)
KR (1) KR20230167064A (pt)
CN (1) CN117396505A (pt)
AU (1) AU2021439970A1 (pt)
BR (1) BR112023020506A2 (pt)
CA (1) CA3215936A1 (pt)
IL (1) IL307291A (pt)
MX (1) MX2023011719A (pt)
WO (1) WO2022216308A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084811B2 (en) * 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN112437664A (zh) * 2018-05-15 2021-03-02 田纳西大学研究基金会 用于治疗胰腺癌的化合物
US20190389841A1 (en) * 2018-05-15 2019-12-26 University Of Tennessee Research Foundation Compounds for treatment of triple negative breast cancer and ovarian cancer
JP7460772B2 (ja) * 2020-04-03 2024-04-02 ヴェル インコーポレイテッド コロナウイルス感染症の治療方法

Also Published As

Publication number Publication date
JP2024512816A (ja) 2024-03-19
WO2022216308A1 (en) 2022-10-13
MX2023011719A (es) 2023-11-09
CN117396505A (zh) 2024-01-12
KR20230167064A (ko) 2023-12-07
EP4320151A1 (en) 2024-02-14
US20240180879A1 (en) 2024-06-06
IL307291A (en) 2023-11-01
CA3215936A1 (en) 2022-10-13
AU2021439970A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
CL2018003213A1 (es) Inhibidores enzimáticos.
MX2022001834A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-1.
BR112018013522A2 (pt) compostos inibidores de metaloenzima
CL2021002100A1 (es) Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1.
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
BR112018012255A2 (pt) método para tratar câncer
BR112022015110A2 (pt) Compostos e usos dos mesmos
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
BR112017013982A2 (pt) fármaco de combinação
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
BR112022025933A2 (pt) Compostos de ligação ao cereblon, composições dos mesmos e métodos de tratamento com os mesmos
BR112022015109A2 (pt) Compostos e usos dos mesmos
BR112022004175A2 (pt) Tratamento de encefalopatia de syngap1
BR112022014949A2 (pt) Compostos e usos dos mesmos
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112023002225A2 (pt) Método para tratar um distúrbio mediado pela ikaros e/ou aiolos
CL2022002410A1 (es) Terapia combinada de inhibidores axl/mer y pd-1/pd-l1.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112023020506A2 (pt) Métodos de tratamento de inflamação
BR112018073627A2 (pt) método para tratar câncer em um paciente
BR112022013480A2 (pt) Métodos de tratamento de coronavírus